Synaptogenix, Inc. (SNPX)

Synaptogenix Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	5.38	6.34	9.81	8.28	8.09	9.84
Research & Development	1.71	1.97	6.32	4.34	3.07	5.67
Operating Expenses	7.08	8.31	16.13	12.62	11.16	15.51
Operating Income	-7.08	-8.31	-16.13	-12.62	-11.16	-15.51
Other Expense / Income	-2.55	-2.28	-10.56	-0.01	1.55	-0.38
Pretax Income	-4.53	-6.04	-5.57	-12.61	-12.7	-15.13
Net Income	-4.53	-6.04	-5.57	-12.61	-12.7	-15.13
Preferred Dividends	7.69	7.74	0.12	0	2.43	0
Net Income Common	-12.23	-13.78	-5.69	-12.61	-15.13	-15.13
Shares Outstanding (Basic)	1	0	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0	0
Shares Change	245.45%	66.71%	39.36%	298.79%	-	-37.52%
EPS (Basic)	-28.41	-29.50	-20.25	-62.75	-300.75	-301.00
EPS (Diluted)	-28.41	-29.50	-20.25	-62.75	-300.75	-301.00
Free Cash Flow	-5.31	-5.18	-11.22	-8.71	-8.11	-11.89
Free Cash Flow Per Share	-5.12	-11.11	-40.13	-43.44	-161.18	-236.41
EBITDA	-4.53	-6.03	-5.57	-12.61	-12.7	-15.13
Depreciation & Amortization	0.01	0.01	0.01	0	0	0
EBIT	-4.53	-6.04	-5.57	-12.61	-12.7	-15.13

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).